Therapy Areas: Diabetes
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
27 November 2025 - Chinese biopharmaceutical company Gan & Lee Pharmaceuticals Co., Ltd. (SHA: 603087) announced on Thursday that it has begun GRADUAL-3, its third large-scale phase 3 study of the...
Novo Nordisk reports strong phase 2 results for amycretin in type 2 diabetes
25 November 2025 - Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Tuesday reported positive phase 2 results for amycretin in people with type 2 diabetes, showing statistical...
Innovent Biologics reports primary and all key secondary endpoints met in mazdutide Phase 3 trial
20 November 2025 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX: 01801) announced on Wednesday that the Phase 3 clinical trial of mazdutide, a first-in-class dual glucagon (GCG)/gluc...
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
18 November 2025 - Clinical-stage biopharmaceutical company Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) on Monday announced results from its joint research with Virginia Commonwealth University (VCU) eva...
Adocia files patent for long-acting peptide platform AdoXLong and updates on BioChaperone studies
12 November 2025 - Adocia (Euronext Paris:ADOC), a clinical-stage biopharmaceutical company focused on diabetes and obesity treatments, on Wednesday announced the filing of a patent for its new long-a...
Renalytix publishes pivotal kidneyintelX.dkd data in Diabetes Care and showcases clinical utility at ASN Kidney Week
12 November 2025 - Precision medicine diagnostics company Renalytix plc (LSE: RENX) (OTCQB: RNLXY) announced on Wednesday the publication of a pivotal study on its FDA-approved and Medicare-reimbursed...